<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JPP</journal-id>
<journal-id journal-id-type="hwp">spjpp</journal-id>
<journal-title>Journal of Pharmacy Practice</journal-title>
<issn pub-type="ppub">0897-1900</issn>
<issn pub-type="epub">1531-1937</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0897190012442722</article-id>
<article-id pub-id-type="publisher-id">10.1177_0897190012442722</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Relative Efficacy of Antilipemic Agents in Non–High-Density Lipoprotein Cholesterol Reduction</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Santee</surname>
<given-names>Jennifer</given-names>
</name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="aff1-0897190012442722">1</xref>
<xref ref-type="corresp" rid="corresp1-0897190012442722"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lindsey</surname>
<given-names>Cameron</given-names>
</name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="aff1-0897190012442722">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pace</surname>
<given-names>Heather</given-names>
</name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="aff1-0897190012442722">1</xref>
</contrib>
<aff id="aff1-0897190012442722"><label>1</label>School of Pharmacy, University of Missouri, Kansas City, MO, USA</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0897190012442722">Jennifer Santee, University of Missouri, 2464 Charlotte St, Kansas City , MO 64108, USA Email: <email>santeej@umkc.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>25</volume>
<issue>4</issue>
<fpage>447</fpage>
<lpage>456</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The investigators sought to summarize the percentage reduction in non–high-density lipoprotein cholesterol (non-HDL-C) achieved with various antilipemic regimens and to determine whether certain antilipemic regimens have been proven more effective in lowering non-HDL-C. A search of MEDLINE, International Pharmaceutical Abstracts, and Iowa Drug Information Service Database from 1970 to May 2011 was performed. Criteria were used to exclude studies not published in English, studies with methodology limitations, and studies with variables that may affect efficacy beyond the antilipemic agent administered. Only randomized, controlled trials comparing medications approved by the Food and Drug Administration were reviewed to determine whether significant differences in percentage reduction in non-HDL-C had been observed between different medication regimens. A total of 51 trials reported data that could be used to determine the range of percentage reduction in non-HDL-C achieved by select antilipemic regimens. Of these 51 trials, 38 provided head-to-head comparisons of antilipemic regimens. Rosuvastatin and atorvastatin are the most potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in lowering non-HDL-C. Adding ezetimibe, fibric acid derivatives, and omega-3 fatty acids to antilipemic monotherapy may result in further reduction in non-HDL-C. Subjects with certain characteristics (eg, nonwhite) were not prevalent in these studies.</p>
</abstract>
<kwd-group>
<kwd>ambulatory care</kwd>
<kwd>cardiology</kwd>
<kwd>internal medicine</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0897190012442722">
<title>Background</title>
<p>The National Cholesterol Education Program published its <italic>Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</italic> (Adult Treatment Panel III or ATP-III) in 2002 and update in 2004.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012442722">1</xref>,<xref ref-type="bibr" rid="bibr2-0897190012442722">2</xref>
</sup> The authors discussed the association between very-low-density lipoprotein cholesterol (VLDL-C) and cardiovascular disease. As a result of this association, the authors suggested using VLDL-C in combination with low-density lipoprotein cholesterol (LDL-C) as a secondary target when addressing cholesterol concentrations. VLDL-C is not routinely monitored but non–high-density lipoprotein cholesterol (non-HDL-C), the sum of VLDL-C and LDL-C, can be easily calculated by subtracting HDL-C concentrations from total cholesterol concentrations.</p>
<p>The Panel preferred non-HDL-C over triglycerides as a target, when triglyceride concentrations are between 200 and 500 mg/dL. Triglycerides should be the target of therapy, when triglyceride concentrations are &gt;500 mg/dL to prevent pancreatitis. Triglyceride concentrations are more affected by fasting status. Non-HDL-C allows for more flexibility in drug therapy selection.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012442722">1</xref>,<xref ref-type="bibr" rid="bibr2-0897190012442722">2</xref>
</sup> Others have questioned whether triglyceride concentrations alone are truly indicative of risk of coronary heart disease.<sup>
<xref ref-type="bibr" rid="bibr3-0897190012442722">3</xref>
</sup> Goals for HDL-C were not provided because the Panel felt that it has not been established whether raising HDL-C alone reduces coronary heart disease risk.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012442722">1</xref>
</sup>
</p>
<p>Some clinicians may want to place even more emphasis on non-HDL-C as a goal of therapy. Two studies have found that non-HDL-C was a better predictor of cardiovascular disease than LDL-C. Non-HDL-C levels may also be more useful than LDL-C as it is less affected by fasting status than LDL-C.<sup>
<xref ref-type="bibr" rid="bibr4-0897190012442722">4</xref>,<xref ref-type="bibr" rid="bibr5-0897190012442722">5</xref>
</sup>
</p>
<p>The ATP-III recommendations provide estimations of the percentage alteration expected for LDL-C, HDL-C, and triglycerides for each drug class but not for non-HDL-C.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012442722">1</xref>
</sup> If lowering non-HDL-C is to be a goal for drug therapy, providers need to consider the extent of alteration in non-HDL-C that is achieved by drug therapy to see whether goals will be met. This article seeks to provide clinicians with the range of non-HDL-C reduction reported in trials investigating various medication regimens. Clinicians will decide upon different medication regimens depending on several factors including cost, tolerability, and efficacy. If efficacy is the determining factor, providers will also need to know whether certain drugs or doses have been proven more effective than others in lowering non-HDL-C. This article also summarizes the results of head-to-head comparisons or active-control studies of medications for dyslipidemias.</p>
</sec>
<sec id="section2-0897190012442722">
<title>Literature Search</title>
<p>A search of MEDLINE, International Pharmaceutical Abstracts, and Iowa Drug Information Service from 1970 to May 2011 was performed using keywords outlined in <xref ref-type="table" rid="table1-0897190012442722">Table 1</xref>. Studies were reviewed to find additional trials. The search was limited to prospective trials with human subjects, which were published in the English language. Studies with the following characteristics were excluded: treatment duration of less than 4 weeks, not reporting percentage change in non-HDL-C for a particular drug (eg, reporting the percentage change for all 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors [statins] but not for a particular statin), exclusively studying a drug that has not been approved by the US Food and Drug Administration (FDA), treatment intervals less than 3 months with less than 4 weeks between treatment intervals, inclusion of only HIV-positive patients, inclusion of only infants, or inclusion of only those patients receiving antipsychotics. If data were reported in 2 different publications, only the publication with more complete data on methods and results was included.</p>
<table-wrap id="table1-0897190012442722" position="float">
<label>Table 1.</label>
<caption>
<p>Keywords Utilized to Identify Pertinent Studies</p>
</caption>
<graphic alternate-form-of="table1-0897190012442722" xlink:href="10.1177_0897190012442722-table1.tif"/>
<table>
<tbody>
<tr>
<td>Atorvastatin</td>
</tr>
<tr>
<td>Cholestyramine</td>
</tr>
<tr>
<td>Colesevelam</td>
</tr>
<tr>
<td>Colestipol</td>
</tr>
<tr>
<td>Docosahexaenoic acid</td>
</tr>
<tr>
<td>Eicosapentaenoic acid</td>
</tr>
<tr>
<td>Ezetimibe</td>
</tr>
<tr>
<td>Fenofibrate</td>
</tr>
<tr>
<td>Fluvastatin</td>
</tr>
<tr>
<td>Gemfibrozil</td>
</tr>
<tr>
<td>Lovastatin</td>
</tr>
<tr>
<td>Niacin</td>
</tr>
<tr>
<td>Nicotinic acid</td>
</tr>
<tr>
<td>Non-HDL</td>
</tr>
<tr>
<td>Non-HDL-C</td>
</tr>
<tr>
<td>Non-HDL-cholesterol</td>
</tr>
<tr>
<td>Pitavastatin</td>
</tr>
<tr>
<td>Pravastatin</td>
</tr>
<tr>
<td>Rosuvastatin</td>
</tr>
<tr>
<td>Simvastatin</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0897190012442722">
<p>HDL, high-density lipoprotein; C, cholesterol.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>All studies identified using the above search strategies were used to summarize the range of percentage reduction seen by investigators. Clinicians can use this data to estimate what percentage reduction they may expect after selecting a certain lipid-lowering regimen.</p>
<p>Since head-to-head comparisons were not made in all studies, only randomized, controlled trials comparing medications approved by the FDA that included a description of how the data were statistically analyzed were reviewed to determine whether the significant differences in percentage reduction in non-HDL-C had been observed between different medication regimens. Post hoc calculation of power was completed if there were no statistically significant differences between the treatment groups to determine whether the sample size was appropriate to detect a statistical difference.</p>
</sec>
<sec id="section3-0897190012442722">
<title>Findings</title>
<p>Utilizing the search strategy described above, 129 articles were identified. Of them, 77 articles were excluded based on the criteria listed above. Only 1 of the excluded articles was not published in the English language. One additional study was excluded from the analysis. Subjects in this study were enrolled at discharge after being hospitalized for a coronary event. Total cholesterol concentrations fall immediately following an acute myocardial infarction and return to baseline within 6–8 weeks.<sup>
<xref ref-type="bibr" rid="bibr6-0897190012442722">6</xref>
</sup> This natural history of change in cholesterol concentration may bias the percentage change in non-HDL-C achieved by antilipemic therapy.</p>
<p>Subject or trial characteristics found in at least half of the remaining 51 trials are summarized in <xref ref-type="table" rid="table2-0897190012442722">Table 2</xref>. Certain subject populations (ie, nonwhite, uncontrolled diabetes, HDL-C &lt;40 mg/dL, triglycerides &gt;200 mg/dL) were not prevalent in these studies. Characteristics listed in <xref ref-type="table" rid="table2-0897190012442722">Table 2</xref> did not differ based on medication class, except for baseline triglycerides. Trials investigating niacin and fibric acid derivatives tended to have mean or median baseline triglyceride concentrations &gt;200 mg/dL, whereas most trials investigating other classes of antilipemic medications had mean or median triglyceride concentrations &lt;200 mg/dL.</p>
<table-wrap id="table2-0897190012442722" position="float">
<label>Table 2.</label>
<caption>
<p>Subject or Trial Characteristics Found in at Least Half of the Included Trials</p>
</caption>
<graphic alternate-form-of="table2-0897190012442722" xlink:href="10.1177_0897190012442722-table2.tif"/>
<table>
<tbody>
<tr>
<td>Greater than 75% of subjects Caucasian<sup><xref ref-type="table-fn" rid="table-fn3-0897190012442722">*</xref></sup>
</td>
</tr>
<tr>
<td>Included subjects from the United States<sup><xref ref-type="table-fn" rid="table-fn4-0897190012442722">†</xref></sup>
</td>
</tr>
<tr>
<td>Mean age between 47 and 64 years of age<sup><xref ref-type="table-fn" rid="table-fn5-0897190012442722">‡</xref></sup>
</td>
</tr>
<tr>
<td>25%-75% of subjects were female<sup><xref ref-type="table-fn" rid="table-fn6-0897190012442722">§</xref></sup>
</td>
</tr>
<tr>
<td>Mean or median baseline BMI ≥27 kg/m<sup>2<xref ref-type="table-fn" rid="table-fn7-0897190012442722">¶</xref></sup>
</td>
</tr>
<tr>
<td>Excluded those with renal or hepatic dysfunction<sup><xref ref-type="table-fn" rid="table-fn8-0897190012442722">**</xref></sup>
</td>
</tr>
<tr>
<td>Excluded those with uncontrolled or unstable diabetes<sup><xref ref-type="table-fn" rid="table-fn9-0897190012442722">††</xref></sup>
</td>
</tr>
<tr>
<td>Monitored compliance with diet and/or study medication<sup><xref ref-type="table-fn" rid="table-fn10-0897190012442722">‡‡</xref></sup>
</td>
</tr>
<tr>
<td>Mean or median baseline lipid concentrations</td>
</tr>
<tr>
<td> HDL-C &gt;40 mg/dL<sup><xref ref-type="table-fn" rid="table-fn11-0897190012442722">§§</xref></sup>
</td>
</tr>
<tr>
<td> Non-HDL-C &gt;190 mg/dL<sup><xref ref-type="table-fn" rid="table-fn12-0897190012442722">¶¶</xref></sup>
</td>
</tr>
<tr>
<td> Triglycerides &lt;200 mg/dL<sup><xref ref-type="table-fn" rid="table-fn13-0897190012442722">***</xref></sup>
</td>
</tr>
<tr>
<td> LDL-C &gt;160 mg/dL<sup><xref ref-type="table-fn" rid="table-fn14-0897190012442722">†††</xref></sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0897190012442722">
<p>Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non–high-density lipoprotein cholesterol.</p>
</fn>
<fn id="table-fn3-0897190012442722">
<p>
<sup>*</sup>
<italic>References</italic> 9, 11, 12, 14-18, 20-26, 29-33, 37, 39, 42, 44, 45, 47, 52-56, 58</p>
</fn>
<fn id="table-fn4-0897190012442722">
<p>
<sup>†</sup>
<italic>References</italic> 9, 11-18, 20-25, 27-32, 36, 37, 39, 43, 45-47, 49, 50, 52, 54, 55, 58.</p>
</fn>
<fn id="table-fn5-0897190012442722">
<p>
<sup>‡</sup>
<italic>References</italic> 7-22, 24-50, 52-57.</p>
</fn>
<fn id="table-fn6-0897190012442722">
<p>
<sup>§</sup>
<italic>References</italic> 8-12, 14-30, 32-35, 38-40, 42-50, 52-58.</p>
</fn>
<fn id="table-fn7-0897190012442722">
<p>
<sup>¶</sup>
<italic>References</italic> 10-18, 24, 25, 27-34, 36-40, 42-46, 48, 49, 52-57.</p>
</fn>
<fn id="table-fn8-0897190012442722">
<p>
<sup>**</sup>
<italic>References</italic> 7-9, 11-14, 17-27, 30-38, 40-48, 50, 52-54, 56-58.</p>
</fn>
<fn id="table-fn9-0897190012442722">
<p>
<sup>††</sup>
<italic>References</italic> 7, 9, 11, 12, 14, 18-24, 26, 27, 29, 30, 32, 34-36, 38, 42-50, 52-54, 56-58</p>
</fn>
<fn id="table-fn10-0897190012442722">
<p>
<sup>‡‡</sup>
<italic>References</italic> 7, 8, 10, 14-17, 20-22, 24, 25, 27, 29-32, 34, 36, 37, 40, 41, 44, 45, 48, 49, 52, 53, 56, 57.</p>
</fn>
<fn id="table-fn11-0897190012442722">
<p>
<sup>§§</sup>
<italic>References</italic> 7, 8, 10-12, 14-27, 29, 30, 32-38, 41-50, 52-54, 56-58.</p>
</fn>
<fn id="table-fn12-0897190012442722">
<p>
<italic>
<sup>¶¶</sup>References</italic> 7-18, 20-36, 38-41, 52-55.</p>
</fn>
<fn id="table-fn13-0897190012442722">
<p>
<sup>***</sup>
<italic>References</italic> 7, 12, 15-26, 30, 32, 33, 35, 41-44, 47-50, 53, 56, 58.</p>
</fn>
<fn id="table-fn14-0897190012442722">
<p>
<sup>†††</sup>
<italic>References</italic> 7, 11-18, 20-26, 30, 32, 35, 36, 40, 41, 52-54.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>All 51 studies can be used to summarize the range of percentage reduction in non-HDL-C reported by investigators. Some trials investigated the initial reduction in non-HDL-C concentrations. Investigators in these trials measured baseline non-HDL-C concentrations, while subjects were not receiving any antilipemic medications. Other trials investigated the additional reduction in non-HDL-C concentrations. Subjects in these trials were receiving antilipemic therapy at baseline. Investigators in these trials measured the change in non-HDL-C after increasing the dose of antilipemic therapy and/or providing additional antilipemic therapy. <xref ref-type="table" rid="table3-0897190012442722">Table 3</xref> summarizes the range of initial percentage change in non-HDL-C reported in 39 of the 51 trials.<sup>
<xref ref-type="bibr" rid="bibr7-0897190012442722">7</xref>
<xref ref-type="bibr" rid="bibr8-0897190012442722"/>
<xref ref-type="bibr" rid="bibr9-0897190012442722"/>
<xref ref-type="bibr" rid="bibr10-0897190012442722"/>
<xref ref-type="bibr" rid="bibr11-0897190012442722"/>
<xref ref-type="bibr" rid="bibr12-0897190012442722"/>
<xref ref-type="bibr" rid="bibr13-0897190012442722"/>
<xref ref-type="bibr" rid="bibr14-0897190012442722"/>
<xref ref-type="bibr" rid="bibr15-0897190012442722"/>
<xref ref-type="bibr" rid="bibr16-0897190012442722"/>
<xref ref-type="bibr" rid="bibr17-0897190012442722"/>
<xref ref-type="bibr" rid="bibr18-0897190012442722"/>
<xref ref-type="bibr" rid="bibr19-0897190012442722"/>
<xref ref-type="bibr" rid="bibr20-0897190012442722"/>
<xref ref-type="bibr" rid="bibr21-0897190012442722"/>
<xref ref-type="bibr" rid="bibr22-0897190012442722"/>
<xref ref-type="bibr" rid="bibr23-0897190012442722"/>
<xref ref-type="bibr" rid="bibr24-0897190012442722"/>
<xref ref-type="bibr" rid="bibr25-0897190012442722"/>
<xref ref-type="bibr" rid="bibr26-0897190012442722"/>
<xref ref-type="bibr" rid="bibr27-0897190012442722"/>
<xref ref-type="bibr" rid="bibr28-0897190012442722"/>
<xref ref-type="bibr" rid="bibr29-0897190012442722"/>
<xref ref-type="bibr" rid="bibr30-0897190012442722"/>
<xref ref-type="bibr" rid="bibr31-0897190012442722"/>
<xref ref-type="bibr" rid="bibr32-0897190012442722"/>
<xref ref-type="bibr" rid="bibr33-0897190012442722"/>
<xref ref-type="bibr" rid="bibr34-0897190012442722"/>
<xref ref-type="bibr" rid="bibr35-0897190012442722"/>
<xref ref-type="bibr" rid="bibr36-0897190012442722"/>
<xref ref-type="bibr" rid="bibr37-0897190012442722"/>
<xref ref-type="bibr" rid="bibr38-0897190012442722"/>
<xref ref-type="bibr" rid="bibr39-0897190012442722"/>
<xref ref-type="bibr" rid="bibr40-0897190012442722"/>–<xref ref-type="bibr" rid="bibr41-0897190012442722">41</xref>,<xref ref-type="bibr" rid="bibr52-0897190012442722">52</xref>
<xref ref-type="bibr" rid="bibr53-0897190012442722"/>
<xref ref-type="bibr" rid="bibr54-0897190012442722"/>–<xref ref-type="bibr" rid="bibr55-0897190012442722">55</xref>
</sup> The percentage reduction achieved by statins, fibric acid derivatives, and ezetimibe monotherapy was similar to what has been demonstrated for LDL-C lowering with these same agents.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012442722">1</xref>
</sup> <xref ref-type="table" rid="table4-0897190012442722">Table 4</xref> summarizes the range of additional percentage change in non-HDL-C reported in the 12 remaining trials.<sup>
<xref ref-type="bibr" rid="bibr42-0897190012442722">42</xref>
<xref ref-type="bibr" rid="bibr43-0897190012442722"/>
<xref ref-type="bibr" rid="bibr44-0897190012442722"/>
<xref ref-type="bibr" rid="bibr45-0897190012442722"/>
<xref ref-type="bibr" rid="bibr46-0897190012442722"/>
<xref ref-type="bibr" rid="bibr47-0897190012442722"/>
<xref ref-type="bibr" rid="bibr48-0897190012442722"/>
<xref ref-type="bibr" rid="bibr49-0897190012442722"/>–<xref ref-type="bibr" rid="bibr50-0897190012442722">50</xref>,<xref ref-type="bibr" rid="bibr56-0897190012442722">56</xref>
<xref ref-type="bibr" rid="bibr57-0897190012442722"/>–<xref ref-type="bibr" rid="bibr58-0897190012442722">58</xref>
</sup> <xref ref-type="table" rid="table3-0897190012442722">Tables 3</xref> and <xref ref-type="table" rid="table4-0897190012442722">4</xref> were compiled by combining results from numerous trials; therefore, while a provider can use these tables to determine what to expect once he or she has selected a certain regimen based on other factors besides relative efficacy, definitive comparisons between antilipemic regimens cannot be made using these 2 tables.</p>
<table-wrap id="table3-0897190012442722" position="float">
<label>Table 3.</label>
<caption>
<p>Ranges of Mean, Median, or Least Square Mean Initial Percentage Change in Non-HDL-C</p>
</caption>
<graphic alternate-form-of="table3-0897190012442722" xlink:href="10.1177_0897190012442722-table3.tif"/>
<table>
<thead>
<tr>
<th>Drug and daily dose (mg)</th>
<th>Reduction in non-HDL-C (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluvastatin 20-80</td>
<td>13-24<sup>12,13</sup>
</td>
</tr>
<tr>
<td>Lovastatin 20-80</td>
<td>22-31<sup>12,13,20</sup>
</td>
</tr>
<tr>
<td>Pravastatin 10-40</td>
<td>17-27<sup>12,13,16,17,21,36</sup>
</td>
</tr>
<tr>
<td>Simvastatin 10-80</td>
<td>24-45<sup>9-13,16-18,22-25,28,37,52-54</sup>
</td>
</tr>
<tr>
<td>Atorvastatin 10-80</td>
<td>33-51<sup>11-19,26,35,41,55</sup>
</td>
</tr>
<tr>
<td>Rosuvastatin 5-80</td>
<td>36-57<sup>14-19,31,32</sup>
</td>
</tr>
<tr>
<td>Pitavastatin 2, 4</td>
<td>36, 41<sup>53</sup>
</td>
</tr>
<tr>
<td>Niacin ER 2000</td>
<td>11-22<sup>31,33</sup>
</td>
</tr>
<tr>
<td>Gemfibrozil 1200</td>
<td>12-20<sup>
<xref ref-type="bibr" rid="bibr7-0897190012442722">7</xref>,40</sup>
</td>
</tr>
<tr>
<td>Fenofibrate 160</td>
<td>14-21<sup>27,29,34</sup>
</td>
</tr>
<tr>
<td>Micronized fenofibrate 130</td>
<td>8<sup>39</sup>
</td>
</tr>
<tr>
<td>Micronized fenofibrate 200</td>
<td>17-19<sup>8,38</sup>
</td>
</tr>
<tr>
<td>Ezetimibe 10</td>
<td>15-20<sup>20-24,27,30</sup>
</td>
</tr>
<tr>
<td>Ezetimibe 10 + colesevelam 3750</td>
<td>27<sup>30</sup>
</td>
</tr>
<tr>
<td>Ezetimibe 10 + fenofibrate 160</td>
<td>30.4<sup>27</sup>
</td>
</tr>
<tr>
<td>Ezetimibe 10 + simvastatin 10-80</td>
<td>42-55<sup>22-26,32-34</sup>
</td>
</tr>
<tr>
<td>Ezetimibe 10 + lovastatin 10-40</td>
<td>38<sup>20</sup>
</td>
</tr>
<tr>
<td>Ezetimibe 10 + pravastatin 10-40</td>
<td>35.6<sup>21</sup>
</td>
</tr>
<tr>
<td>Niacin ER 1000-2000 + rosuvastatin 10-40</td>
<td>38-49<sup>31,32</sup>
</td>
</tr>
<tr>
<td>Niacin ER 1000 + atorvastatin 40</td>
<td>55<sup>32</sup>
</td>
</tr>
<tr>
<td>Simvastatin 20 + fenofibrate 160</td>
<td>35.3<sup>54</sup>
</td>
</tr>
<tr>
<td>Simvastatin 10 + fenofibrate 200</td>
<td>36<sup>28</sup>
</td>
</tr>
<tr>
<td>Rosuvastatin 5 + fenofibrate 135</td>
<td>40.1<sup>52</sup>
</td>
</tr>
<tr>
<td>Rosuvastatin 10 + fenofibrate 135</td>
<td>45.9<sup>52</sup>
</td>
</tr>
<tr>
<td>Rosuvastatin 20 + fenofibrate 135</td>
<td>47.2<sup>52</sup>
</td>
</tr>
<tr>
<td>Fenofibrate 160 + colesevelam 3750</td>
<td>21<sup>29</sup>
</td>
</tr>
<tr>
<td>Ezetimibe 10 + simvastatin 20 + niacin 2000</td>
<td>56<sup>33</sup>
</td>
</tr>
<tr>
<td>Ezetimibe 10 + simvastatin 20 + fenofibrate 160</td>
<td>51<sup>34</sup>
</td>
</tr>
<tr>
<td>Omega-3-acid ethyl esters 4000 + atorvastatin 10</td>
<td>40.2<sup>55</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn15-0897190012442722">
<p>Abbreviations: ER, extended-release; Non-HDL-C, non–high-density lipoprotein cholesterol.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0897190012442722" position="float">
<label>Table 4.</label>
<caption>
<p>Ranges of Mean, Median, or Least Square Mean Additional Percentage Change in Non-HDL-C<sup><xref ref-type="bibr" rid="bibr42-0897190012442722">42</xref><xref ref-type="bibr" rid="bibr43-0897190012442722"/><xref ref-type="bibr" rid="bibr44-0897190012442722"/><xref ref-type="bibr" rid="bibr45-0897190012442722"/><xref ref-type="bibr" rid="bibr46-0897190012442722"/><xref ref-type="bibr" rid="bibr47-0897190012442722"/><xref ref-type="bibr" rid="bibr48-0897190012442722"/><xref ref-type="bibr" rid="bibr49-0897190012442722"/>–<xref ref-type="bibr" rid="bibr50-0897190012442722">50</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table4-0897190012442722" xlink:href="10.1177_0897190012442722-table4.tif"/>
<table>
<thead>
<tr>
<th>Initial drug therapy</th>
<th>Additional drug and daily dose (mg)</th>
<th>Additional reduction in non-HDL-C (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statin</td>
<td>Niacin 1000</td>
<td>14<sup>
<xref ref-type="bibr" rid="bibr46-0897190012442722">46</xref>
</sup>
</td>
</tr>
<tr>
<td>Statin</td>
<td>Niacin 2000</td>
<td>21-23<sup>42,46</sup>
</td>
</tr>
<tr>
<td>Statin</td>
<td>Fenofibrate 160</td>
<td>14.1<sup>57</sup>
</td>
</tr>
<tr>
<td>Statin</td>
<td>Ezetimibe 10</td>
<td>20-28<sup>43,44,47,48,50,56,</sup>
<sup>58</sup>
</td>
</tr>
<tr>
<td>Statin</td>
<td>Omega-3 fatty acids 4000</td>
<td>9<sup>45</sup>
</td>
</tr>
<tr>
<td>Various<sup><xref ref-type="table-fn" rid="table-fn17-0897190012442722">a</xref></sup>
</td>
<td>Colesevelam 3750</td>
<td>8<sup>49</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn16-0897190012442722">
<p>Abbreviations: Non-HDL-C = non–high-density lipoprotein cholesterol.</p>
</fn>
<fn id="table-fn17-0897190012442722">
<p>
<sup>a</sup> Subjects could be receiving statin, fibrates, niacin, fish oils, or other bile-acid sequestrants as therapy.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Randomized controlled trials comparing at least 2 different FDA-approved antilipemic regimens should be used to make definitive comparisons when selecting therapy based on relative efficacy. Of the 51 trials identified above, 37 trials met this criterion.<sup>
<xref ref-type="bibr" rid="bibr12-0897190012442722">12</xref>
<xref ref-type="bibr" rid="bibr13-0897190012442722"/>
<xref ref-type="bibr" rid="bibr14-0897190012442722"/>
<xref ref-type="bibr" rid="bibr15-0897190012442722"/>
<xref ref-type="bibr" rid="bibr16-0897190012442722"/>
<xref ref-type="bibr" rid="bibr17-0897190012442722"/>
<xref ref-type="bibr" rid="bibr18-0897190012442722"/>
<xref ref-type="bibr" rid="bibr19-0897190012442722"/>
<xref ref-type="bibr" rid="bibr20-0897190012442722"/>
<xref ref-type="bibr" rid="bibr21-0897190012442722"/>
<xref ref-type="bibr" rid="bibr22-0897190012442722"/>
<xref ref-type="bibr" rid="bibr23-0897190012442722"/>
<xref ref-type="bibr" rid="bibr24-0897190012442722"/>
<xref ref-type="bibr" rid="bibr25-0897190012442722"/>
<xref ref-type="bibr" rid="bibr26-0897190012442722"/>
<xref ref-type="bibr" rid="bibr27-0897190012442722"/>
<xref ref-type="bibr" rid="bibr28-0897190012442722"/>
<xref ref-type="bibr" rid="bibr29-0897190012442722"/>
<xref ref-type="bibr" rid="bibr30-0897190012442722"/>
<xref ref-type="bibr" rid="bibr31-0897190012442722"/>
<xref ref-type="bibr" rid="bibr32-0897190012442722"/>
<xref ref-type="bibr" rid="bibr33-0897190012442722"/>–<xref ref-type="bibr" rid="bibr34-0897190012442722">34</xref>,<xref ref-type="bibr" rid="bibr43-0897190012442722">43</xref>
<xref ref-type="bibr" rid="bibr44-0897190012442722"/>
<xref ref-type="bibr" rid="bibr45-0897190012442722"/>
<xref ref-type="bibr" rid="bibr46-0897190012442722"/>
<xref ref-type="bibr" rid="bibr47-0897190012442722"/>–<xref ref-type="bibr" rid="bibr48-0897190012442722">48</xref>,<xref ref-type="bibr" rid="bibr50-0897190012442722">50</xref>,<xref ref-type="bibr" rid="bibr54-0897190012442722">54</xref>,<xref ref-type="bibr" rid="bibr56-0897190012442722">56</xref>,<xref ref-type="bibr" rid="bibr57-0897190012442722">57</xref>
</sup> <xref ref-type="table" rid="table5-0897190012442722">Table 5</xref> describes the 27 studies reporting the initial percentage change in non-HDL-C. The percentage change reported in these 27 trials was the difference from baseline (not receiving antilipemic drug therapy) to end point. <xref ref-type="table" rid="table6-0897190012442722">Table 6</xref> describes the 10 studies reporting the additional percentage change in non-HDL-C. The percentage change reported in these 10 trials was the additional reduction with either an increase in dose or additional therapy. All 37 trials included in this portion of the review used appropriate statistical analysis.</p>
<table-wrap id="table5-0897190012442722" position="float">
<label>Table 5.</label>
<caption>
<p>Randomized Trials Comparing Initial Reduction in Non-HDL-C by Antilipemic Agents</p>
</caption>
<graphic alternate-form-of="table5-0897190012442722" xlink:href="10.1177_0897190012442722-table5.tif"/>
<graphic alternate-form-of="table5-0897190012442722" xlink:href="10.1177_0897190012442722-table5a.tif"/>
<table>
<thead>
<tr>
<th>Reference</th>
<th>Design</th>
<th>Number of subjects</th>
<th>Treatment groups</th>
<th>Reduction in non-HDL-C<sup><xref ref-type="table-fn" rid="table-fn19-0897190012442722">a</xref></sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="5">Ballantyne et al<sup>
<xref ref-type="bibr" rid="bibr12-0897190012442722">12</xref>
</sup>
</td>
<td rowspan="5">OL, P</td>
<td rowspan="5">3916</td>
<td>Fluvastatin 20 mg</td>
<td>17.0</td>
</tr>
<tr>
<td>Lovastatin 20 mg</td>
<td>24.1</td>
</tr>
<tr>
<td>Pravastatin 10 mg</td>
<td>17.2</td>
</tr>
<tr>
<td>Simvastatin 10 mg</td>
<td>26.6</td>
</tr>
<tr>
<td>Atorvastatin 10 mg</td>
<td>38-51</td>
</tr>
<tr>
<td rowspan="5">Schaefer et al<sup>
<xref ref-type="bibr" rid="bibr13-0897190012442722">13</xref>
</sup>
</td>
<td rowspan="5">OL, C</td>
<td rowspan="5">99</td>
<td>Fluvastatin 20-80 mg</td>
<td>13-24</td>
</tr>
<tr>
<td>Lovastatin 20-80 mg</td>
<td>22-31</td>
</tr>
<tr>
<td>Pravastatin 20-40 mg</td>
<td>20-25</td>
</tr>
<tr>
<td>Simvastatin 20-40 mg</td>
<td>30-39</td>
</tr>
<tr>
<td>Atorvastatin 20-80 mg</td>
<td>38-51</td>
</tr>
<tr>
<td rowspan="2">Schwartz et al<sup>
<xref ref-type="bibr" rid="bibr14-0897190012442722">14</xref>
</sup>
</td>
<td rowspan="2">DB, P</td>
<td rowspan="2">383</td>
<td>Atorvastatin 10 mg</td>
<td>32.6</td>
</tr>
<tr>
<td>Rosuvastatin 5, 10 mg</td>
<td>36.3, 42.6</td>
</tr>
<tr>
<td rowspan="2">Schneck et al<sup>
<xref ref-type="bibr" rid="bibr15-0897190012442722">15</xref>
</sup>
</td>
<td rowspan="2">DB, P</td>
<td rowspan="2">374</td>
<td>Atorvastatin 10-80 mg</td>
<td>35.9-50.0</td>
</tr>
<tr>
<td>Rosuvastatin 5-80 mg</td>
<td>38.1-57.0</td>
</tr>
<tr>
<td rowspan="4">Blasetto et al<sup>
<xref ref-type="bibr" rid="bibr16-0897190012442722">16</xref>
</sup>
</td>
<td rowspan="4">Pooled analysis of R, DB, P trials</td>
<td rowspan="4">1182</td>
<td>Pravastatin 20 mg</td>
<td>25.0</td>
</tr>
<tr>
<td>Simvastatin 20 mg</td>
<td>32.5</td>
</tr>
<tr>
<td>Atorvastatin 10 mg</td>
<td>33.9</td>
</tr>
<tr>
<td>Rosuvastatin 5, 10 mg</td>
<td>37.0-44.0</td>
</tr>
<tr>
<td rowspan="4">Jones et al<sup>
<xref ref-type="bibr" rid="bibr17-0897190012442722">17</xref>
</sup>
</td>
<td rowspan="4">OL, P</td>
<td rowspan="4">2268</td>
<td>Pravastatin 10-40 mg</td>
<td>18.6-27.4</td>
</tr>
<tr>
<td>Simvastatin 10-80 mg</td>
<td>26.0-41.8</td>
</tr>
<tr>
<td>Atorvastatin 10-80 mg</td>
<td>34.4-48.1</td>
</tr>
<tr>
<td>Rosuvastatin 10-80 mg</td>
<td>42.0-50.9</td>
</tr>
<tr>
<td rowspan="5">Ballantyne et al<sup>
<xref ref-type="bibr" rid="bibr18-0897190012442722">18</xref>
</sup>
</td>
<td rowspan="5">OL, P </td>
<td rowspan="5">1993</td>
<td>Simvastatin 20 mg </td>
<td>30.8</td>
</tr>
<tr>
<td>Simvastatin 40 mg</td>
<td>36.7</td>
</tr>
<tr>
<td>Atorvastatin 10 mg</td>
<td>33.7</td>
</tr>
<tr>
<td>Atorvastatin 20 mg</td>
<td>39.6</td>
</tr>
<tr>
<td>Rosuvastatin 20 mg</td>
<td>47.2</td>
</tr>
<tr>
<td rowspan="4">Betteridge et al<sup>
<xref ref-type="bibr" rid="bibr19-0897190012442722">19</xref>
</sup>
</td>
<td rowspan="4">DB, P</td>
<td rowspan="4">456</td>
<td>Rosuvastatin 10 mg</td>
<td>45.4</td>
</tr>
<tr>
<td>Atorvastatin 10 mg</td>
<td>35.5</td>
</tr>
<tr>
<td>Rosuvastatin 20 mg</td>
<td>50.6</td>
</tr>
<tr>
<td>Atorvastatin 20 mg</td>
<td>41.5</td>
</tr>
<tr>
<td rowspan="4">Kerzner et al<sup>
<xref ref-type="bibr" rid="bibr20-0897190012442722">20</xref>
</sup>
</td>
<td rowspan="4">DB, P </td>
<td rowspan="4">548</td>
<td>Placebo</td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn20-0897190012442722">b</xref></sup>
</td>
</tr>
<tr>
<td>Ezetimibe 10 mg</td>
<td>16</td>
</tr>
<tr>
<td>Lovastatin 10-40 mg</td>
<td>23</td>
</tr>
<tr>
<td>Ezetimibe 10 mg + lovastatin 10-40 mg</td>
<td>38</td>
</tr>
<tr>
<td rowspan="4">Melani et al<sup>
<xref ref-type="bibr" rid="bibr21-0897190012442722">21</xref>
</sup>
</td>
<td rowspan="4">DB, P</td>
<td rowspan="4">538</td>
<td>Placebo</td>
<td>0.1</td>
</tr>
<tr>
<td>Ezetimibe 10 mg</td>
<td>17.2</td>
</tr>
<tr>
<td>Pravastatin 10-40 mg</td>
<td>22.7</td>
</tr>
<tr>
<td>Ezetimibe 10 mg + pravastatin 10-40 mg</td>
<td>35.6</td>
</tr>
<tr>
<td rowspan="4">Davidson et al<sup>
<xref ref-type="bibr" rid="bibr22-0897190012442722">22</xref>
</sup>
</td>
<td rowspan="4">DB, P </td>
<td rowspan="4">668</td>
<td>Placebo</td>
<td>0.7</td>
</tr>
<tr>
<td>Ezetimibe 10 mg</td>
<td>17.4</td>
</tr>
<tr>
<td>Simvastatin 10-80 mg</td>
<td>33.6</td>
</tr>
<tr>
<td>Ezetimibe 10 mg + simvastatin 10-80 mg</td>
<td>47.1</td>
</tr>
<tr>
<td rowspan="4">Goldberg et al<sup>
<xref ref-type="bibr" rid="bibr23-0897190012442722">23</xref>
</sup>
</td>
<td rowspan="4">DB, P </td>
<td rowspan="4">887</td>
<td>Placebo</td>
<td>2.3<sup><xref ref-type="table-fn" rid="table-fn20-0897190012442722">b</xref></sup>
</td>
</tr>
<tr>
<td>Ezetimibe 10 mg</td>
<td>18.6</td>
</tr>
<tr>
<td>Simvastatin 10-80 mg</td>
<td>34.1</td>
</tr>
<tr>
<td>Ezetimibe 10 mg + simvastatin 10-80 mg</td>
<td>48.5</td>
</tr>
<tr>
<td rowspan="4">Bays et al<sup>
<xref ref-type="bibr" rid="bibr24-0897190012442722">24</xref>
</sup>
</td>
<td rowspan="4">DB, P</td>
<td rowspan="4">1528</td>
<td>Placebo</td>
<td>1.6</td>
</tr>
<tr>
<td>Ezetimibe 10 mg</td>
<td>17.6</td>
</tr>
<tr>
<td>Simvastatin 10-80 mg</td>
<td>35.9</td>
</tr>
<tr>
<td>Ezetimibe 10 mg + simvastatin 10-80 mg</td>
<td>48.6</td>
</tr>
<tr>
<td rowspan="2">Feldman et al<sup>
<xref ref-type="bibr" rid="bibr25-0897190012442722">25</xref>
</sup>
</td>
<td rowspan="2">DB<sup><xref ref-type="table-fn" rid="table-fn21-0897190012442722">c</xref></sup>, P</td>
<td rowspan="2">710</td>
<td>Simvastatin 20 mg</td>
<td>34</td>
</tr>
<tr>
<td>Ezetimibe 10 mg + simvastatin 10-40 mg </td>
<td>42-53</td>
</tr>
<tr>
<td rowspan="2">Ballantyne et al<sup>
<xref ref-type="bibr" rid="bibr26-0897190012442722">26</xref>
</sup>
</td>
<td rowspan="2">DB, P </td>
<td rowspan="2">788</td>
<td>Atorvastatin 10-80 mg</td>
<td>35.1-50.3</td>
</tr>
<tr>
<td>Ezetimibe 10 mg + simvastatin 10-80 mg</td>
<td>42.7-55.3</td>
</tr>
<tr>
<td rowspan="4">Farnier et al<sup>
<xref ref-type="bibr" rid="bibr27-0897190012442722">27</xref>
</sup>
</td>
<td rowspan="4">DB, P </td>
<td rowspan="4">625</td>
<td>Placebo</td>
<td>0.2</td>
</tr>
<tr>
<td>Ezetimibe 10 mg</td>
<td>14.7</td>
</tr>
<tr>
<td>Fenofibrate 160 mg</td>
<td>16.2</td>
</tr>
<tr>
<td>Ezetimibe 10 mg + fenofibrate 160 mg</td>
<td>30.4</td>
</tr>
<tr>
<td rowspan="2">Vega et al<sup>
<xref ref-type="bibr" rid="bibr28-0897190012442722">28</xref>
</sup>
</td>
<td rowspan="2">DB, C</td>
<td rowspan="2">20</td>
<td>Simvastatin 10 mg</td>
<td>30</td>
</tr>
<tr>
<td>Simvastatin 10 mg + fenofibrate 200 mg </td>
<td>36</td>
</tr>
<tr>
<td rowspan="2">McKenney et al<sup>
<xref ref-type="bibr" rid="bibr29-0897190012442722">29</xref>
</sup>
</td>
<td rowspan="2">DB, P </td>
<td rowspan="2">129</td>
<td>Fenofibrate 160 mg</td>
<td>14.4</td>
</tr>
<tr>
<td>Fenofibrate 160 mg + colesevelam 3750 mg</td>
<td>21.0</td>
</tr>
<tr>
<td rowspan="2">Bays et al<sup>
<xref ref-type="bibr" rid="bibr30-0897190012442722">30</xref>
</sup>
</td>
<td rowspan="2">DB, P </td>
<td rowspan="2">86</td>
<td>Ezetimibe 10 mg</td>
<td>19.5</td>
</tr>
<tr>
<td>Ezetimibe 10 mg + colesevelam 3750 mg</td>
<td>26.7</td>
</tr>
<tr>
<td rowspan="4">Capuzzi et al<sup>
<xref ref-type="bibr" rid="bibr31-0897190012442722">31</xref>
</sup>
</td>
<td rowspan="4">OL, P </td>
<td rowspan="4">270</td>
<td>Niacin ER 2000 mg </td>
<td>11</td>
</tr>
<tr>
<td>Rosuvastatin 40 mg</td>
<td>49</td>
</tr>
<tr>
<td>Rosuvastatin 10 mg + niacin ER 2000 mg</td>
<td>38</td>
</tr>
<tr>
<td>Rosuvastatin 40 mg + niacin ER 1000 mg</td>
<td>47</td>
</tr>
<tr>
<td rowspan="4">McKenney et al<sup>
<xref ref-type="bibr" rid="bibr32-0897190012442722">32</xref>
</sup>
</td>
<td rowspan="4">OL, P</td>
<td rowspan="4">270</td>
<td>Atorvastatin 40 mg + niacin ER 2000 mg</td>
<td>55</td>
</tr>
<tr>
<td>Rosuvastatin 20 mg + niacin ER 1000 mg</td>
<td>49</td>
</tr>
<tr>
<td>Simvastatin 40 mg + ezetimibe 10 mg</td>
<td>54</td>
</tr>
<tr>
<td>Rosuvastatin 40 mg</td>
<td>50</td>
</tr>
<tr>
<td rowspan="3">Guyton et al<sup>
<xref ref-type="bibr" rid="bibr33-0897190012442722">33</xref>
</sup>
</td>
<td rowspan="3">DB, P</td>
<td rowspan="3">1112</td>
<td>Niacin 2000 mg</td>
<td>22.0<sup><xref ref-type="table-fn" rid="table-fn22-0897190012442722">d</xref></sup>
</td>
</tr>
<tr>
<td>Ezetimibe 10 mg + simvastatin 20 mg</td>
<td>47.9</td>
</tr>
<tr>
<td>Ezetimibe 10 mg + simvastatin 20 mg + niacin 2000 mg</td>
<td>55.6</td>
</tr>
<tr>
<td rowspan="4">Farnier et al<sup>
<xref ref-type="bibr" rid="bibr34-0897190012442722">34</xref>
</sup>
</td>
<td rowspan="4">DB, P</td>
<td rowspan="4">599</td>
<td>Placebo</td>
<td>1.7</td>
</tr>
<tr>
<td>Simvastatin 20 mg + ezetimibe 10 mg</td>
<td>45.2</td>
</tr>
<tr>
<td>Fenofibrate 160 mg</td>
<td>21.0</td>
</tr>
<tr>
<td>Simvastatin 20 mg + ezetimibe 10 mg + fenofibrate 160 mg </td>
<td>50.5</td>
</tr>
<tr>
<td rowspan="4">Roth et al<sup>
<xref ref-type="bibr" rid="bibr52-0897190012442722">52</xref>
</sup>
</td>
<td rowspan="4">DB, P </td>
<td rowspan="4">474</td>
<td>Simvastatin 40 mg</td>
<td>32.6</td>
</tr>
<tr>
<td>Rosuvsatatin 5 mg + fenofibrate 135 mg</td>
<td>40.1</td>
</tr>
<tr>
<td>Rosuvastatin 10 mg + fenofibrate 135 mg</td>
<td>45.9</td>
</tr>
<tr>
<td>Rosuvastatin 20 mg + fenofibrate 135 mg</td>
<td>47.2</td>
</tr>
<tr>
<td rowspan="4">Ose et al<sup>
<xref ref-type="bibr" rid="bibr53-0897190012442722">53</xref>
</sup>
</td>
<td rowspan="4">DB, P</td>
<td rowspan="4">857</td>
<td>Pitavastatin 2 mg</td>
<td>35.8</td>
</tr>
<tr>
<td>Pitavastatin 4 mg</td>
<td>40.5</td>
</tr>
<tr>
<td>Simvastatin 20 mg</td>
<td>32.3</td>
</tr>
<tr>
<td>Simvastatin 40 mg</td>
<td>39.4</td>
</tr>
<tr>
<td rowspan="2">Gundy et al<sup>
<xref ref-type="bibr" rid="bibr54-0897190012442722">54</xref>
</sup>
</td>
<td rowspan="2">DB, P</td>
<td rowspan="2">619</td>
<td>Simvastatin 20 mg</td>
<td>26.1</td>
</tr>
<tr>
<td>Simvastatin 20 mg + fenofibrate 160 mg</td>
<td>35.3</td>
</tr>
<tr>
<td rowspan="2">Bays et al<sup>
<xref ref-type="bibr" rid="bibr55-0897190012442722">55</xref>
</sup>
</td>
<td rowspan="2">DB, P</td>
<td rowspan="2">245</td>
<td>Atorvastatin 10 mg</td>
<td>40.2</td>
</tr>
<tr>
<td>Omega-3-acid ethyl ester + atorvastatin 10 mg</td>
<td>33.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn18-0897190012442722">
<p>Abbreviations: C, crossover; DB, double-blind; ER, extended release; mg, milligrams; Non-HDL-C, non–high-density lipoprotein cholesterol; OL, open label; P, parallel groups.</p>
</fn>
<fn id="table-fn19-0897190012442722">
<p>
<sup>a</sup> Percentage reduction is either the mean percentage change or least squares mean percentage change. Patients not receiving antilipemic therapy at baseline.</p>
</fn>
<fn id="table-fn20-0897190012442722">
<p>
<sup>b</sup> Increase in non-HDL-C.</p>
</fn>
<fn id="table-fn21-0897190012442722">
<p>
<sup>c</sup> Treatment with ezetimibe was blinded. Subjects not blinded to the dose of simvastatin they received.</p>
</fn>
<fn id="table-fn22-0897190012442722">
<p>
<sup>d</sup> Subjects were titrated from lower doses of niacin. Subjects had received the dose of niacin listed in this table for 12 weeks.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table6-0897190012442722" position="float">
<label>Table 6.</label>
<caption>
<p>Randomized Trials Comparing Additional Reduction Non-HDL-C by Antilipemic Agents</p>
</caption>
<graphic alternate-form-of="table6-0897190012442722" xlink:href="10.1177_0897190012442722-table6.tif"/>
<table>
<thead>
<tr>
<th>Reference</th>
<th>Design</th>
<th>Number of subjects</th>
<th>Initial therapy</th>
<th>Additional therapy</th>
<th>Reduction in non-HDL-with additional therapy<sup><xref ref-type="table-fn" rid="table-fn24-0897190012442722">a</xref></sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="2">Gaudiani et al<sup>
<xref ref-type="bibr" rid="bibr43-0897190012442722">43</xref>
</sup>
</td>
<td rowspan="2">DB, P</td>
<td rowspan="2">214</td>
<td rowspan="2">Simvastatin 20 mg</td>
<td>Simvastatin 40 mg</td>
<td>1.7</td>
</tr>
<tr>
<td>Simvastatin 20 mg + ezetimibe 10 mg</td>
<td>20.0</td>
</tr>
<tr>
<td rowspan="2">Cruz-Fernandez et al<sup>
<xref ref-type="bibr" rid="bibr44-0897190012442722">44</xref>
</sup>
</td>
<td rowspan="2">DB, P</td>
<td rowspan="2">450</td>
<td rowspan="2">Atorvastatin 10 or 20 mg</td>
<td>Atorvastatin 10 or 20 mg</td>
<td>3.2</td>
</tr>
<tr>
<td>Atorvastatin 10 or 20 mg + ezetimibe 10 mg</td>
<td>27.6</td>
</tr>
<tr>
<td rowspan="2">Davidson et al<sup>
<xref ref-type="bibr" rid="bibr45-0897190012442722">45</xref>
</sup>
</td>
<td rowspan="2">DB, P</td>
<td rowspan="2">256</td>
<td rowspan="2">Simvastatin 40 mg</td>
<td>Simvastatin 40 mg</td>
<td>1.5</td>
</tr>
<tr>
<td>Simvastatin 40 mg + omega-3 fatty acids 4000 mg</td>
<td>7.9</td>
</tr>
<tr>
<td rowspan="3">Ballantyne et al<sup>
<xref ref-type="bibr" rid="bibr46-0897190012442722">46</xref>
</sup>
</td>
<td rowspan="3">DB, P</td>
<td rowspan="3">319</td>
<td rowspan="3">Simvastatin 20 mg</td>
<td>Simvastatin 20 mg</td>
<td>7.4</td>
</tr>
<tr>
<td>Simvastatin 20 mg + niacin ER 1000 mg</td>
<td>13.9</td>
</tr>
<tr>
<td>Simvastatin 20 mg + niacin ER 2000 mg</td>
<td>22.5</td>
</tr>
<tr>
<td rowspan="2">Leiter et al<sup>
<xref ref-type="bibr" rid="bibr47-0897190012442722">47</xref>
</sup>
</td>
<td rowspan="2">DB, P</td>
<td rowspan="2">556</td>
<td rowspan="2">Atorvastatin 40 mg</td>
<td>Atorvastatin 40 mg + ezetimibe 10 mg</td>
<td>23</td>
</tr>
<tr>
<td>Atorvastatin 80 mg</td>
<td>9</td>
</tr>
<tr>
<td rowspan="3">Constance et al<sup>
<xref ref-type="bibr" rid="bibr48-0897190012442722">48</xref>
</sup>
</td>
<td rowspan="3">DB, P</td>
<td rowspan="3">657</td>
<td rowspan="3">Atorvastatin 10 mg</td>
<td>Simvastatin 20 mg + ezetimibe 10 mg</td>
<td>20.91</td>
</tr>
<tr>
<td>Simvastatin 40 mg + ezetimibe 10 mg</td>
<td>23.80</td>
</tr>
<tr>
<td>Atorvastatin 20 mg</td>
<td>7.43</td>
</tr>
<tr>
<td rowspan="2">Conard et al<sup>
<xref ref-type="bibr" rid="bibr50-0897190012442722">50</xref>
</sup>
</td>
<td rowspan="2">DB, P</td>
<td rowspan="2">184</td>
<td rowspan="2">Atorvastatin 20 mg</td>
<td>Atorvastatin 20 mg + ezetimibe 10 mg</td>
<td>27</td>
</tr>
<tr>
<td>Atorvastatin 40 mg</td>
<td>10</td>
</tr>
<tr>
<td rowspan="2">Farnier et al<sup>
<xref ref-type="bibr" rid="bibr56-0897190012442722">56</xref>
</sup>
</td>
<td rowspan="2">DB, P</td>
<td rowspan="2">618</td>
<td rowspan="2">Various statins</td>
<td>Simvastatin 20 mg + ezetimibe 10 mg</td>
<td>23.4</td>
</tr>
<tr>
<td>Rosuvastatin 10 mg</td>
<td>14.0</td>
</tr>
<tr>
<td rowspan="2">Farnier et al<sup>
<xref ref-type="bibr" rid="bibr57-0897190012442722">57</xref>
</sup>
</td>
<td rowspan="2">DB, P</td>
<td rowspan="2">248</td>
<td rowspan="2">Pravastatin 40 mg</td>
<td>Pravastatin 40 mg</td>
<td>6.1</td>
</tr>
<tr>
<td>Pravastatin 40 mg + fenofibrate 160 mg</td>
<td>14.1</td>
</tr>
<tr>
<td rowspan="2">Zieve et al<sup>
<xref ref-type="bibr" rid="bibr58-0897190012442722">58</xref>
</sup>
</td>
<td rowspan="2">DB, P</td>
<td rowspan="2">1053</td>
<td rowspan="2">Atorvastatin 10 mg</td>
<td>Atorvastatin 10 mg + ezetimibe 10 mg</td>
<td>24</td>
</tr>
<tr>
<td>Atorvastatin 20 mg</td>
<td>11</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn23-0897190012442722">
<p>Abbreviations: C, crossover; DB, double-blind; mg, milligrams; OL, open label; Non-HDL-C, non–high-density lipoprotein cholesterol; P, parallel groups.</p>
</fn>
<fn id="table-fn24-0897190012442722">
<p>
<sup>a</sup> Percentage reduction is either the mean percentage change or least squares mean percentage change.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section4-0897190012442722">
<title>Statin Versus Statin</title>
<p>
<xref ref-type="table" rid="table7-0897190012442722">Table 7</xref> details whether investigators have found a statistically significant difference between different doses of different statins with respect to non-HDL-C reduction.<sup>
<xref ref-type="bibr" rid="bibr12-0897190012442722">12</xref>
<xref ref-type="bibr" rid="bibr13-0897190012442722"/>
<xref ref-type="bibr" rid="bibr14-0897190012442722"/>
<xref ref-type="bibr" rid="bibr15-0897190012442722"/>
<xref ref-type="bibr" rid="bibr16-0897190012442722"/>
<xref ref-type="bibr" rid="bibr17-0897190012442722"/>
<xref ref-type="bibr" rid="bibr18-0897190012442722"/>–<xref ref-type="bibr" rid="bibr19-0897190012442722">19</xref>,<xref ref-type="bibr" rid="bibr53-0897190012442722">53</xref>
</sup> Not all possible comparisons between statins were made in the included trials (eg, investigators did not report whether the differences between pravastatin and simvastatin were statistically significant). One trial did not find a statistically significant difference between pitavastatin 4 mg and simvastatin 40 mg but lacked sufficient power to detect a difference.<sup>
<xref ref-type="bibr" rid="bibr53-0897190012442722">53</xref>
</sup>
</p>
<table-wrap id="table7-0897190012442722" position="float">
<label>Table 7.</label>
<caption>
<p>Relative Potency of Statins<sup><xref ref-type="bibr" rid="bibr12-0897190012442722">12</xref><xref ref-type="bibr" rid="bibr13-0897190012442722"/><xref ref-type="bibr" rid="bibr14-0897190012442722"/><xref ref-type="bibr" rid="bibr15-0897190012442722"/><xref ref-type="bibr" rid="bibr16-0897190012442722"/><xref ref-type="bibr" rid="bibr17-0897190012442722"/><xref ref-type="bibr" rid="bibr18-0897190012442722"/>–<xref ref-type="bibr" rid="bibr19-0897190012442722">19</xref>,<xref ref-type="bibr" rid="bibr53-0897190012442722">53</xref>,<xref ref-type="table-fn" rid="table-fn26-0897190012442722">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table7-0897190012442722" xlink:href="10.1177_0897190012442722-table7.tif"/>
<table>
<thead>
<tr>
<th>This dose of this statin (mg)</th>
<th>Has been shown to result in a greater percentage reduction in non-HDL-C than those doses of these statins (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>R (5)</td>
<td>A (10), S (20), P (20)</td>
</tr>
<tr>
<td>R (10)</td>
<td>A (10), S (10), S (20), S (40), P (10), P (20), P (40)</td>
</tr>
<tr>
<td>R (20)</td>
<td>A (10), A (20), S (20), S (40), S (80), P (20), P (40)</td>
</tr>
<tr>
<td>R (40)</td>
<td>S (40), S (80), P (40)</td>
</tr>
<tr>
<td>A (10)</td>
<td>S (10), L (20), F (20)</td>
</tr>
<tr>
<td>A (20)</td>
<td>P (20), L (20), F (20)</td>
</tr>
<tr>
<td>A (40)</td>
<td>P (40), L (40), F (40)</td>
</tr>
<tr>
<td>A (80)</td>
<td>P (40), L (80), F (80)</td>
</tr>
<tr>
<td>Pit (2)</td>
<td>S (20)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn25-0897190012442722">
<p>Abbreviations: A, atorvastatin, F, fluvastatin, L, lovastatin, non-HDL-C, non–high-density lipoprotein cholesterol, P, pravastatin, Pit, pitavastatin, S, simvastatin, R, rosuvastatin.</p>
</fn>
<fn id="table-fn26-0897190012442722">
<p>
<sup>a</sup> All differences in potencies had <italic>P</italic> ≤.05</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-0897190012442722">
<title>Coadministration of Ezetimibe and a Statin</title>
<p>One trial found that adding ezetimibe to a statin resulted in an additional reduction in non-HDL-C beyond using a statin alone (<italic>P</italic> &lt; 0.001).<sup>
<xref ref-type="bibr" rid="bibr44-0897190012442722">44</xref>
</sup> Seven trials found that using the combination of ezetimibe and a statin produced a greater initial percentage reduction in non-HDL-C than using monotherapy of the statin at the same dose (<italic>P</italic> &lt; 0.05).<sup>
<xref ref-type="bibr" rid="bibr20-0897190012442722">20</xref>,<xref ref-type="bibr" rid="bibr22-0897190012442722">22</xref>
<xref ref-type="bibr" rid="bibr23-0897190012442722"/>–<xref ref-type="bibr" rid="bibr24-0897190012442722">24</xref>,<xref ref-type="bibr" rid="bibr26-0897190012442722">26</xref>
</sup> Combining ezetimibe with a statin resulted in a greater percentage reduction in non-HDL-C than doubling the dose of the same statin (<italic>P</italic> &lt; 0.001). <sup>
<xref ref-type="bibr" rid="bibr24-0897190012442722">24</xref>,<xref ref-type="bibr" rid="bibr25-0897190012442722">25</xref>,<xref ref-type="bibr" rid="bibr43-0897190012442722">43</xref>,<xref ref-type="bibr" rid="bibr47-0897190012442722">47</xref>, <xref ref-type="bibr" rid="bibr50-0897190012442722">50</xref>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr58-0897190012442722">58</xref>
</sup> Constance et al determined that switching subjects from atorvastatin 10 mg daily to a combination of ezetimibe and either simvastatin 20 or 40 mg daily resulted in a greater percentage reduction than increasing the dose of atorvastatin to 20 mg daily (<italic>P</italic> &lt; 0.001).<sup>
<xref ref-type="bibr" rid="bibr48-0897190012442722">48</xref>
</sup> Farnier et al observed that switching to the combination of ezetimibe and simvastatin 20 mg led to a greater additional percentage reduction than switching to rosuvastatin 10 mg alone (<italic>P</italic> &lt; 0.001).<sup>
<xref ref-type="bibr" rid="bibr56-0897190012442722">56</xref>
</sup>
</p>
</sec>
<sec id="section6-0897190012442722">
<title>Coadministration With Bile Acid Sequestrants</title>
<p>Coadministration of colesevelam with ezetimibe resulted in a greater reduction in non-HDL-C than ezetimibe alone (<italic>P</italic> = .0024).<sup>
<xref ref-type="bibr" rid="bibr30-0897190012442722">30</xref>
</sup> McKenney et al observed that the combination of fenofibrate and colesevelam led to a significantly greater reduction in non-HDL-C than fenofibrate monotherapy (<italic>P</italic> &lt; .0001). Each treatment group was divided into subjects with baseline triglyceride concentrations of &lt;200 mg/dL and subjects with baseline triglyceride concentrations &gt;200 mg/dL. The difference between combination therapy and fenofibrate monotherapy was significantly different for those with baseline triglyceride concentrations of &gt;200 mg/dL (<italic>P</italic> = .0116) but not for those with baseline triglyceride concentrations of &lt;200 mg/dL (<italic>P</italic> = .1883). The investigators did not calculate power for this part of the analysis. Post hoc calculations to determine whether power was sufficient to detect a difference could not be made due to insufficient data.<sup>
<xref ref-type="bibr" rid="bibr29-0897190012442722">29</xref>
</sup>
</p>
</sec>
<sec id="section7-0897190012442722">
<title>Coadministration With Fibric Acid Derivatives</title>
<p>Vega et al compared simvastatin 10 mg daily to combination therapy with simvastatin 10 mg daily and fenofibrate 200 mg daily. Monotherapy and combination therapy had significantly greater reductions in non-HDL-C compared with placebo (<italic>P</italic> &lt; .01), but no difference was seen between monotherapy and combination therapy (<italic>P</italic> value not provided). The investigators did not calculate power for this part of the analysis. Post hoc calculations revealed insufficient power to detect a difference (power = 28%).<sup>
<xref ref-type="bibr" rid="bibr28-0897190012442722">28</xref>
</sup>
</p>
<p>In contrast, 2 other studies reported significantly greater reductions in non-HDL-C, when 160 mg of fenofibrate was added to statin therapy. (<italic>P</italic> &lt; .05).<sup>
<xref ref-type="bibr" rid="bibr54-0897190012442722">54</xref>,<xref ref-type="bibr" rid="bibr57-0897190012442722">57</xref>
</sup>
</p>
<p>In 2005, Farnier et al compared placebo, ezetimibe 10 mg daily, micronized fenofibrate 160 mg daily, and the combination of ezetimibe 10 mg daily and micronized fenofibrate 160 mg daily. Significantly greater reduction in non-HDL-C was seen for the combination therapy compared with either ezetimibe or fenofibrate monotherapy (<italic>P</italic> &lt; .001). No significant difference was detected comparing ezetimibe and fenofibrate monotherapy (<italic>P</italic> &gt; 0.05). The investigators did not calculate power for comparing non-HDL-C reduction. Post hoc calculations could not be made due to insufficient data. The ezetimibe and fenofibrate combination therapy group and the fenofibrate monotherapy group had more women and fewer patients with diabetes mellitus type 2. Baseline triglyceride concentrations did not appear to affect percentage reduction in non-HDL-C.<sup>
<xref ref-type="bibr" rid="bibr27-0897190012442722">27</xref>
</sup>
</p>
<p>In 2007, Farnier et al compared placebo, fenofibrate 160 mg daily, the combination of ezetimibe 10 mg daily with simvastatin 20 mg daily, and the combination of ezetimibe 10 mg daily, simvastatin 20 mg daily, and fenofibrate 160 mg daily. The triple combination of ezetimibe, simvastatin, and fenofibrate had the largest percentage reduction in non-HDL-C, followed by the dual combination of ezetimibe and simvastatin and then fenofibrate monotherapy (<italic>P</italic> &lt; .01).<sup>
<xref ref-type="bibr" rid="bibr34-0897190012442722">34</xref>
</sup>
</p>
<p>Roth et al observed that various doses of rosuvastatin (5, 10, and 20 mg daily) combined with fenofibric acid 135 mg daily resulted in a more significant decrease in non-HDL-C than simvastatin 40 mg alone (<italic>P</italic> ≤ .001).<sup>
<xref ref-type="bibr" rid="bibr52-0897190012442722">52</xref>
</sup>
</p>
</sec>
<sec id="section8-0897190012442722">
<title>Coadministration With Niacin</title>
<p>Capuzzi et al observed that rosuvastatin 40 mg daily alone resulted in a significantly greater reduction in non-HDL-C than extended-release niacin 2000 mg daily alone (<italic>P</italic> &lt; .001) or extended-release niacin 2000 mg daily coadministered with rosuvastatin 10 mg daily (<italic>P</italic> &lt; .01). Coadministering extended-release niacin 1000 mg daily with rosuvastatin 40 mg daily did not lead to a significantly greater reduction in non-HDL-C when compared with rosuvastatin 40 mg daily monotherapy (<italic>P</italic> &gt; .017). Post hoc calculations revealed sufficient power to detect a difference (power &gt;90%).<sup>
<xref ref-type="bibr" rid="bibr31-0897190012442722">31</xref>
</sup>
</p>
<p>Ballantyne et al determined that adding either niacin 1000 or 2000 mg daily to simvastatin 20 mg daily resulted in a significantly greater reduction in non-HDL-C than just continuing simvastatin 20 mg daily (<italic>P</italic> &lt; .01).<sup>
<xref ref-type="bibr" rid="bibr46-0897190012442722">46</xref>
</sup>
</p>
<p>McKenney et al did not detect a significant difference between atorvastatin 20 mg daily administered with extended-release niacin 1000 mg daily, rosuvastatin 10 mg daily administered with extended-release niacin 1000 mg daily, simvastatin 20 mg daily administered with ezetimibe 10 mg daily, and rosuvastatin 20 mg daily (<italic>P</italic> = .322). Although this study lacked sufficient power to detect a statistically significant difference, the absolute differences observed in the trial, which ranged from 1% to 6%, are not likely to be clinically significant.<sup>
<xref ref-type="bibr" rid="bibr32-0897190012442722">32</xref>
</sup>
</p>
<p>Guyton et al observed that triple combination of ezetimibe 10 mg daily, simvastatin 20 mg daily, and extended-release niacin 2000 mg daily led to a greater reduction compared with niacin 2000 mg daily alone or dual treatment with ezetimibe 10 mg daily and simvastatin 20 mg daily (<italic>P</italic> &lt; .001).<sup>
<xref ref-type="bibr" rid="bibr33-0897190012442722">33</xref>
</sup>
</p>
</sec>
<sec id="section9-0897190012442722">
<title>Coadministration With Omega-3 Fatty Acids</title>
<p>Davidson et al investigated the difference in additional percentage reduction when omega-3 fatty acids 4000 mg daily were added to simvastatin 40 mg. The addition of omega-3 fatty acids led to a significantly greater reduction in non-HDL-C than simvastatin 40 mg daily monotherapy (<italic>P</italic> &lt; .001).<sup>
<xref ref-type="bibr" rid="bibr45-0897190012442722">45</xref>
</sup> Bays et al observed that adding 4000 mg of omega-3-acid ethyl esters to atorvastatin 10 mg resulted in a significantly greater reduction in non-HDL-C than monotherapy with atorvastatin 10 mg (<italic>P</italic> &lt; .001).<sup>
<xref ref-type="bibr" rid="bibr55-0897190012442722">55</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section10-0897190012442722">
<title>Limitations of Trials</title>
<p>Limitations of some of these trials include insufficient power or lack of power calculation, no discussion of numbers of withdrawals and/or reasons for withdrawals, lack of exclusion or control for all possible confounding factors, lack of comparison of the treatment groups with respect to all potential confounding factors, funding by the pharmaceutical company, and lack of assessment of compliance with diet or medication. Subjects in the trial by Schwartz et al underwent a forced titration in dose as long as LDL-C was &gt;50 mg/dL. Not all subjects were titrated to the higher doses. Rosuvastatin still led to a significantly greater reduction in non-HDL-C even though a lower percentage of patients were titrated to higher doses.<sup>
<xref ref-type="bibr" rid="bibr14-0897190012442722">14</xref>
</sup> Potential bias could have been present in the work by Jones et al, as this was a post hoc analysis of a previously published work, which did not include the analysis of non-HDL-C concentrations in the prior publication.<sup>
<xref ref-type="bibr" rid="bibr17-0897190012442722">17</xref>
</sup>
</p>
<p>Subjects in the majority of these trials had triglyceride concentrations &lt;200 mg/dL. Whether the percentage reduction in non-HDL-C differs based on triglyceride concentrations is not known. Therefore, the results seen in these trials may not be similar to the results seen in the patients for whom non-HDL-C would be the focus of therapy (ie, LDL-C at goal, triglycerides between 200 and 500 mg/dL). Clinicians should also review the literature on whether an antilipemic agent has been shown to decrease morbidity and mortality in deciding upon appropriate therapy for a patient.</p>
</sec>
<sec id="section11-0897190012442722">
<title>Conclusion</title>
<p>The ATP-III report recommended clinicians target non-HDL-C as a secondary goal. Non-HDL-C may be a better predictor than LDL-C due to the fact that it takes into consideration the more atherogenic lipoproteins than LDL-C.<sup>
<xref ref-type="bibr" rid="bibr4-0897190012442722">4</xref>,<xref ref-type="bibr" rid="bibr5-0897190012442722">5</xref>
</sup> References provide percentage reductions expected for LDL-C, HDL-C, and triglycerides but not routinely non-HDL-C. If non-HDL-C is to be a goal of therapy, clinicians need to be aware of how antilipemic agents affect non-HDL-C.</p>
<p>Factors such as tolerability and cost may be more pertinent issues than relative efficacy in non-HDL-C reduction for particular patients. Therefore, the clinician in this scenario may need to know to what extent a certain medication may lower non-HDL-C to set reasonable goals for the therapy. <xref ref-type="table" rid="table3-0897190012442722">Table 3</xref> in this article provides a summary of what to expect when starting a certain antilipemic regimen. <xref ref-type="table" rid="table4-0897190012442722">Table 4</xref> in this article provides a summary of what to expect when adding medication to an established antilipemic regimen.</p>
<p>Clinicians may choose therapy based on relative efficacy in non-HDL-C reduction when other factors are not as pertinent. <xref ref-type="table" rid="table5-0897190012442722">Tables 5</xref> and <xref ref-type="table" rid="table6-0897190012442722">6</xref> summarize the trials in which regimens have been compared head to head. Such trials have demonstrated that rosuvastatin is the most potent statin for lowering non-HDL-C, followed by atorvastatin. Adding ezetimibe to statin therapy results in further reduction in non-HDL-C compared with using the same statin as monotherapy and a greater reduction in non-HDL-C than simply doubling the dose of the same statin. These findings reflect what is seen for LDL-C reduction.<sup>
<xref ref-type="bibr" rid="bibr1-0897190012442722">1</xref>,<xref ref-type="bibr" rid="bibr2-0897190012442722">2</xref>
</sup>
</p>
<p>The addition of bile acid sequestrants, fibric acid derivatives, and omega-3 fatty acids to antilipemic-monotherapy likely leads to further reduction in non-HDL-C concentrations. Conflicting results from trials observing the change in non-HDL-C with the addition of niacin to other antilipemic medications prevent firm conclusions about the effect of concomitant therapy with niacin.</p>
<p>An even more important factor in selecting an antilipemic regimen beyond cost, tolerability, and relative efficacy in lowering non-HDL-C is whether a select regimen has been shown to decrease morbidity and mortality. For example, the addition of ezetimibe to statin does lower non-HDL-C more but whether it offers additional reduction in morbidity and mortality is not clear.<sup>
<xref ref-type="bibr" rid="bibr51-0897190012442722">51</xref>
</sup> Clinicians should review the literature on morbidity and mortality as well when making decisions regarding therapy.</p>
<p>The results of these studies cannot be applied to certain subject populations as these groups were not prevalent in these studies. Further research should include more subjects to determine whether the effects of lipid-lowering medications on non-HDL-C differ depending on patient characteristics. Clinicians providing care for those who are HIV positive or receiving antipsychotics are encouraged to review the literature further as this review did not focus on these patient subsets.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0897190012442722">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0897190012442722">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article </p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0897190012442722">
<label>1</label>
<citation citation-type="book">
<collab collab-type="author">National Cholesterol Education Program</collab>. <source>Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</source>. <publisher-loc>Bethesda, MD</publisher-loc>: <publisher-name>National Heart, Lung, and Blood Institute</publisher-name>; 2002. <comment>NIH Pub. No. 02-5215</comment>.</citation>
</ref>
<ref id="bibr2-0897190012442722">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Cleeman</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Bairey Merz</surname>
<given-names>CN</given-names>
</name>
<etal/>
</person-group> <article-title>Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>110</volume>(<issue>2</issue>):<fpage>227</fpage>–<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr3-0897190012442722">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Avins</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Neuhaus</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Do triglycerides provide meaningful information about heart disease risk?</article-title> <source>Arch Intern Med</source>. <year>2000</year>;<volume>160</volume>(<issue>13</issue>):<fpage>1937</fpage>–<lpage>1944</lpage>.</citation>
</ref>
<ref id="bibr4-0897190012442722">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Blumenthal</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Flaws</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group> <article-title>Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality</article-title>. <source>Arch Intern Med</source>. <year>2001</year>;<volume>161</volume>(<issue>11</issue>):<fpage>1413</fpage>–<lpage>1419</lpage>.</citation>
</ref>
<ref id="bibr5-0897190012442722">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Resnick</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Jablonski</surname>
<given-names>KA</given-names>
</name>
<etal/>
</person-group> <article-title>Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2003</year>;<volume>26</volume>(<issue>1</issue>):<fpage>16</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr6-0897190012442722">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Scragg</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Changes in serum lipid concentrations during the first 24 hours after myocardial infarction</article-title>. <source>Br Med J</source>. <year>1987</year>;<volume>294</volume>(<issue>6857</issue>):<fpage>1588</fpage>–<lpage>1589</lpage>.</citation>
</ref>
<ref id="bibr7-0897190012442722">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frick</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Elo</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Haapa</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia</article-title>. <source>N Engl J Med</source>. <year>1987</year>;<volume>317</volume>(<issue>20</issue>):<fpage>1237</fpage>–<lpage>1245</lpage>.</citation>
</ref>
<ref id="bibr8-0897190012442722">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koh</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Quon</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group> <article-title>Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia</article-title>. <source>Diabetes Care</source>. <year>2005</year>;<volume>28</volume>(<issue>6</issue>):<fpage>1419</fpage>–<lpage>1424</lpage>.</citation>
</ref>
<ref id="bibr9-0897190012442722">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isaacsohn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hunninghake</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schrott</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of simvastatin, an HMG-CoA-reductase inhibitor, in patients with hypertriglyceridemia</article-title>. <source>Clin Cardiol</source>. <year>2003</year>;<volume>26</volume>(<issue>1</issue>):<fpage>18</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr10-0897190012442722">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solfrizzi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Capurso</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Colacicco</surname>
<given-names>AM</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and tolerability of combined treatment with l-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus</article-title>. <source>Atherosclerosis</source>. <year>2006</year>;<volume>188</volume>(<issue>2</issue>):<fpage>455</fpage>–<lpage>461</lpage>.</citation>
</ref>
<ref id="bibr11-0897190012442722">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunninghake</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Ballantyne</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Maccubbin</surname>
<given-names>DL</given-names>
</name>
<etal/>
</person-group> <article-title>Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome</article-title>. <source>Clin Ther</source>. <year>2003</year>;<volume>25</volume>(<issue>6</issue>):<fpage>1670</fpage>–<lpage>1686</lpage>.</citation>
</ref>
<ref id="bibr12-0897190012442722">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballantyne</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Hsia</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group> <article-title>Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels</article-title>. <source>Am J Cardiol</source>. <year>2001</year>:<volume>88</volume>(<issue>3</issue>):<fpage>265</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr13-0897190012442722">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaefer</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>McNamara</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Tayler</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart diseases versus control subjects</article-title>. <source>Am J Cardiol</source>. <year>2004</year>;<volume>93</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr14-0897190012442722">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Bolognese</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>BP</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial</article-title>. <source>Am Heart J</source>. <year>2004</year>;<volume>148</volume>(<issue>1</issue>):<fpage>e4</fpage>.</citation>
</ref>
<ref id="bibr15-0897190012442722">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneck</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Knopp</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Ballantyne</surname>
<given-names>CM</given-names>
</name>
<etal/>
</person-group> <article-title>Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease</article-title>. <source>Am J Cardiol</source>. <year>2003</year>;<volume>91</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr16-0897190012442722">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blasetto</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>WV</given-names>
</name>
<etal/>
</person-group>. <article-title>Efficacy of rosuvastatin compared with other statins at select starting doses in hypercholesterolemic patients and in special population groups</article-title>. <source>Am J Cardiol</source>. <year>2003</year>;<volume>91</volume>(<issue>5A</issue>):<fpage>3C</fpage>–<lpage>10C</lpage>.</citation>
</ref>
<ref id="bibr17-0897190012442722">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Hunninghake</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Ferdinand</surname>
<given-names>KC</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial</article-title>. <source>Clin Ther</source>. <year>2004</year>;<volume>26</volume>(<issue>9</issue>):<fpage>1388</fpage>–<lpage>1399</lpage>.</citation>
</ref>
<ref id="bibr18-0897190012442722">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballantyne</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Bertolami</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hernandez Garcia</surname>
<given-names>HR</given-names>
</name>
<etal/>
</person-group> <article-title>Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY) II</article-title>. <source>Am Heart J</source>. <year>2006</year>;<volume>151</volume>(<issue>5</issue>):<fpage>e1</fpage>–<lpage>e9</lpage>.</citation>
</ref>
<ref id="bibr19-0897190012442722">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Betteridge</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes</article-title>. <source>Diabet Med</source>. <year>2007</year>;<volume>24</volume>(<issue>5</issue>):<fpage>541</fpage>–<lpage>549</lpage>.</citation>
</ref>
<ref id="bibr20-0897190012442722">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerzner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Corbelli</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia</article-title>. <source>Am J Cardiol</source>. <year>2003</year>;<volume>91</volume>(<issue>4</issue>):<fpage>418</fpage>–<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr21-0897190012442722">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hassman</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial</article-title>. <source>Eur Heart J</source>. <year>2003</year>;<volume>24</volume>(<issue>8</issue>):<fpage>717</fpage>–<lpage>728</lpage>.</citation>
</ref>
<ref id="bibr22-0897190012442722">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>McGarry</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bettis</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia</article-title>. <source>J Am Coll Cardiol</source>. <year>2002</year>;<volume>40</volume>(<issue>12</issue>):<fpage>2125</fpage>–<lpage>2134</lpage>.</citation>
</ref>
<ref id="bibr23-0897190012442722">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldberg</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Sapre</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial</article-title>. <source>Mayo Clin Proc</source>. <year>2004</year>;<volume>79</volume>(<issue>5</issue>):<fpage>620</fpage>–<lpage>629</lpage>.</citation>
</ref>
<ref id="bibr24-0897190012442722">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bays</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Ose</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fraser</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia</article-title>. <source>Clin Ther</source>. <year>2004</year>;<volume>26</volume>(<issue>11</issue>):<fpage>1758</fpage>–<lpage>1773</lpage>.</citation>
</ref>
<ref id="bibr25-0897190012442722">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldman</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Koren</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Insull</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group> <article-title>Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals</article-title>. <source>Am J Cardiol</source>. <year>2004</year>;<volume>93</volume>(<issue>12</issue>):<fpage>1481</fpage>–<lpage>1486</lpage>.</citation>
</ref>
<ref id="bibr26-0897190012442722">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballantyne</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Blazing</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>King</surname>
<given-names>TR</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia</article-title>. <source>Am J Cardiol</source>. <year>2004</year>;<volume>93</volume>(<issue>12</issue>):<fpage>1487</fpage>–<lpage>1494</lpage>.</citation>
</ref>
<ref id="bibr27-0897190012442722">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farnier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Macdonell</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia</article-title>. <source>Eur Heart J</source>. <year>2005</year>;<volume>26</volume>(<issue>9</issue>):<fpage>897</fpage>–<lpage>905</lpage>.</citation>
</ref>
<ref id="bibr28-0897190012442722">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vega</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>PTS</given-names>
</name>
<name>
<surname>Cater</surname>
<given-names>NB</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome</article-title>. <source>Am J Cardiol</source>. <year>2003</year>;<volume>91</volume>(<issue>8</issue>):<fpage>956</fpage>–<lpage>960</lpage>.</citation>
</ref>
<ref id="bibr29-0897190012442722">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKenney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abby</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia</article-title>. <source>Curr Med Res Opin</source>. <year>2005</year>;<volume>21</volume>(<issue>9</issue>):<fpage>1403</fpage>–<lpage>1412</lpage>.</citation>
</ref>
<ref id="bibr30-0897190012442722">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bays</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rhyne</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abby</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Lipid-lowering effects of colesevelam HCl in combination with ezetimibe</article-title>. <source>Curr Med Res Opin</source>. <year>2006</year>;<volume>22</volume>(<issue>11</issue>):<fpage>2191</fpage>–<lpage>2200</lpage>.</citation>
</ref>
<ref id="bibr31-0897190012442722">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capuzzi</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group> <article-title>Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels</article-title>. <source>Am J Cardiol</source>. <year>2003</year>;<volume>91</volume>(<issue>11</issue>):<fpage>1304</fpage>–<lpage>1310</lpage>.</citation>
</ref>
<ref id="bibr32-0897190012442722">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKenney</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Bays</surname>
<given-names>HE</given-names>
</name>
<etal/>
</person-group> <article-title>Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)</article-title>. <source>Atherosclerosis</source>. <year>2007</year>;<volume>192</volume>(<issue>2</issue>):<fpage>432</fpage>–<lpage>437</lpage>.</citation>
</ref>
<ref id="bibr33-0897190012442722">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guyton</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Fazio</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>51</volume>(<issue>16</issue>):<fpage>1564</fpage>–<lpage>1572</lpage>.</citation>
</ref>
<ref id="bibr34-0897190012442722">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farnier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gil-Extremera</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia</article-title>. <source>Am Heart J</source>. <year>2007</year>;<volume>153</volume>(<issue>2</issue>):335.<fpage>e1</fpage>–<lpage>335</lpage>.e8.</citation>
</ref>
<ref id="bibr35-0897190012442722">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Save</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Patil</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Moulik</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of atorvastatin on type 2 diabetic dyslipidemia</article-title>. <source>J Cardiovasc Pharmacol Ther</source>. <year>2006</year>;<volume>11</volume>(<issue>4</issue>):<fpage>262</fpage>–<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr36-0897190012442722">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Testolin</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Maki</surname>
<given-names>KC</given-names>
</name>
<etal/>
</person-group> <article-title>A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women</article-title>. <source>Arch Intern Med</source>. <year>1997</year>;<volume>157</volume>(<issue>11</issue>):<fpage>1186</fpage>–<lpage>1192</lpage>.</citation>
</ref>
<ref id="bibr37-0897190012442722">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Insull</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>PM</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia</article-title>. <source>Metabolism</source>. <year>2005</year>;<volume>54</volume>(<issue>7</issue>):<fpage>939</fpage>–<lpage>946</lpage>.</citation>
</ref>
<ref id="bibr38-0897190012442722">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filippatos</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Kiortsis</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Liberopoulos</surname>
<given-names>EN</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study</article-title>. <source>Curr Med Res Opin</source>. <year>2005</year>;<volume>21</volume>(<issue>12</issue>):<fpage>1997</fpage>–<lpage>2006</lpage>.</citation>
</ref>
<ref id="bibr39-0897190012442722">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Bays</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects</article-title>. <source>Clin Cardiol</source>. <year>2006</year>;<volume>29</volume>(<issue>6</issue>):<fpage>268</fpage>–<lpage>273</lpage>.</citation>
</ref>
<ref id="bibr40-0897190012442722">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguilar-Salinas</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Fanghänel-Salmón</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Edilberto</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study</article-title>. <source>Metabolism</source> <year>2001</year>;<volume>50</volume>(<issue>6</issue>):<fpage>729</fpage>–<lpage>733</lpage>.</citation>
</ref>
<ref id="bibr41-0897190012442722">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasaki</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kuribayashi</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance</article-title>. <source>Clin Ther</source>. <year>2008</year>;<volume>30</volume>(<issue>6</issue>):<fpage>1089</fpage>–<lpage>1101</lpage>.</citation>
</ref>
<ref id="bibr42-0897190012442722">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karas</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Kashyap</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Knopp</surname>
<given-names>RH</given-names>
</name>
<etal/>
</person-group> <article-title>Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia</article-title>. <source>Am J Cardiovasc Drugs</source>. <year>2008</year>;<volume>8</volume>(<issue>2</issue>):<fpage>69</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr43-0897190012442722">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaudiani</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Lewin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Meneghini</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients</article-title>. <source>Diabetes Obes Metab</source>. <year>2005</year>;<volume>7</volume>(<issue>1</issue>):<fpage>88</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr44-0897190012442722">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cruz-Fernandez</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Bedarida</surname>
<given-names>GV</given-names>
</name>
<name>
<surname>Adgey</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease</article-title>. <source>Int J Clin Pract</source>. <year>2005</year>;<volume>59</volume>(<issue>6</issue>):<fpage>619</fpage>–<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr45-0897190012442722">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Bays</surname>
<given-names>HE</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study</article-title>. <source>Clin Ther</source>. <year>2007</year>;<volume>29</volume>(<issue>7</issue>):<fpage>1354</fpage>–<lpage>1367</lpage>.</citation>
</ref>
<ref id="bibr46-0897190012442722">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballantyne</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>McKenney</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs. simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOST I Study)</article-title>. <source>Am J Cardiol</source>. <year>2008</year>;<volume>101</volume>(<issue>10</issue>):<fpage>1428</fpage>–<lpage>1436</lpage>.</citation>
</ref>
<ref id="bibr47-0897190012442722">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leiter</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Bays</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Conard</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at risk of coronary heart disease</article-title>. <source>Am J Cardiol</source>. <year>2008</year>;<volume>102</volume>(<issue>11</issue>):<fpage>1495</fpage>–<lpage>1501</lpage>.</citation>
</ref>
<ref id="bibr48-0897190012442722">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Constance</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Westphal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus</article-title>. <source>Diabetes Obes Metab</source>. <year>2007</year>;<volume>9</volume>(<issue>4</issue>):<fpage>575</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr49-0897190012442722">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bays</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Truitt</surname>
<given-names>KE</given-names>
</name>
<etal/>
</person-group> <article-title>Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin</article-title>. <source>Arch Intern Med</source>. <year>2008</year>;<volume>168</volume>(<issue>18</issue>):<fpage>1975</fpage>–<lpage>1983</lpage>.</citation>
</ref>
<ref id="bibr50-0897190012442722">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conard</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Bays</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Leiter</surname>
<given-names>LA</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease</article-title>. <source>Am J Cardiol</source>. <year>2008</year>;<volume>102</volume>(<issue>11</issue>):<fpage>1489</fpage>–<lpage>1494</lpage>.</citation>
</ref>
<ref id="bibr51-0897190012442722">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al</surname>
<given-names>Bardarin</given-names>
</name>
<name>
<surname>Kullo</surname>
<given-names>IJ</given-names>
</name>
<name>
<surname>Kopecky</surname>
<given-names>SL</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of ezetimibe on atherosclerosis: is the jury still out?</article-title> <source>Mayo Clin Proc</source>. <year>2009</year>;<volume>84</volume>(<issue>4</issue>):<fpage>353</fpage>–<lpage>361</lpage>. </citation>
</ref>
<ref id="bibr52-0897190012442722">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roth</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>McKenney</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>MT</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy and safety of rosuvastation and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hyptertriglyceridemia</article-title>. <source>Am J Cardiovasc Drugs</source>. <year>2010</year>;<volume>10</volume>(<issue>3</issue>):<fpage>175</fpage>–<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr53-0897190012442722">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ose</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Budinski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hounslow</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidemia</article-title>. <source>Curr Med Res Opin</source>. <year>2009</year>;<volume>25</volume>(<issue>11</issue>):<fpage>2755</fpage>–<lpage>2764</lpage>.</citation>
</ref>
<ref id="bibr54-0897190012442722">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gundy</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Vega</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group> <article-title>Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI trial)</article-title>. <source>Am J Cardiol</source>. <year>2005</year>;<volume>95</volume>(<issue>4</issue>):<fpage>462</fpage>–<lpage>468</lpage>.</citation>
</ref>
<ref id="bibr55-0897190012442722">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bays</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>McKenney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Maki</surname>
<given-names>KC</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin</article-title>. <source>Mayo Clin Proc</source>. <year>2010</year>;<volume>85</volume>(<issue>2</issue>):<fpage>122</fpage>–<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr56-0897190012442722">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farnier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Averna</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Missault</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy—the in-cross study</article-title>. <source>Int J Clin Pract</source>. <year>2009</year>;<volume>63</volume>(<issue>4</issue>):<fpage>547</fpage>–<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr57-0897190012442722">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farnier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ducobu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bryniarski</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy</article-title>. <source>Am J Cardiol</source>. <year>2010</year>;<volume>106</volume>(<issue>6</issue>):<fpage>787</fpage>–<lpage>792</lpage>.</citation>
</ref>
<ref id="bibr58-0897190012442722">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zieve</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wenger</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Ben-Yehuda</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group> <article-title>Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients ≥ 65 years of age (from the ZETia in the ELDerly (ZETELD) study)</article-title>. <source>Am J Cardiol</source>. <year>2010</year>;<volume>105</volume>(<issue>5</issue>):<fpage>656</fpage>–<lpage>663</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>